The US BGI import ban took effect on 29 October 2026, barring goods from three Chinese genomics companies from entering the United States unless importers can rebut a legal presumption that the goods were made with forced labour. The United States Department of Homeland Security (DHS) added BGI Genomics, MGI Tech and Shenzhen BGI Technology, also known as BGI Group, to the Uyghur Forced Labor Prevention Act (UFLPA) Entity List on 28 October 2026. The story is trending per news coverage from Reuters and other outlets, because it brings together a major genomics industry, a human rights allegation that China strongly denies, and a fresh point of friction in US-China trade. China condemned the move on 29 October, while the companies denied the allegations.
In plain terms, the listing does not name every customer or every product. It applies a presumption at the United States border: goods from the three listed companies are treated as prohibited unless the importer meets the law's requirements to show that they were not made with forced labour. US Customs and Border Protection (CBP) is instructed to stop goods from the listed companies from entering the United States unless that presumption can be rebutted. The measure is an import restriction under United States law. It is not, on its own, a blanket ban on the companies' products in every market, although buyers and partners outside the United States may still reassess supply-chain risk because of the listing.
What the US BGI Import Ban Does From 29 October 2026
From 29 October 2026, CBP applies the rebuttable presumption to goods produced by BGI Genomics, MGI Tech and Shenzhen BGI Technology. That date matters for shipments already in transit and for orders placed before the announcement, because the question at the border is no longer only what a product is, but whether the importer can produce evidence that satisfies the UFLPA requirements. DHS said in its announcement: "Today, DHS is barring three Chinese DNA testing companies from allowing their goods to enter the United States unless importers can meet the law's requirements," in the words of Homeland Security Secretary Markwayne Mullin. Rob Law, the DHS under secretary who chairs the Forced Labor Enforcement Task Force, said goods produced by the companies "will not be allowed entry unless they can prove that they do not take part in the forced labor apparatus in Xinjiang."
DHS posted the additions in the Federal Register, the United States government's official daily journal, on 28 October 2026. With the three genomics companies added, the UFLPA Entity List now covers 190 entities, according to reporting on the DHS notice. The list spans a wide range of products, from cotton and canned tomatoes to electronics, and DHS had already added 43 entities on 31 July 2026, which it described as the largest single expansion since the list was created. The genomics additions are therefore unusual not because the list is new, but because they extend it into DNA sequencing and genetic testing, where the products are instruments, reagents and testing services rather than familiar consumer goods.
Why the US BGI Import Ban Names BGI Genomics, MGI Tech and BGI Group
The United States allegation, as set out in the DHS notice, is specific. DHS said the government had "reasonable cause to believe, based on specific and articulable information," that BGI Genomics conducts genetic testing in the Xinjiang Uyghur Autonomous Region (XUAR) alongside the government of the region and as part of its government initiatives. DHS said such testing was used to facilitate the recruitment, transport, transfer, harbouring or receiving of forced labour involving Uyghurs, Kazakhs, Kyrgyz and members of other persecuted groups out of Xinjiang. MGI Tech, DHS said, had provisioned genetic testing capacity to the XUAR government, and provides equipment and related support for that testing. These are United States government allegations underlying the designation. They are not presented here as independent judicial findings that the companies committed forced labour, and the companies deny them.
DHS also described how the three names fit together. BGI Group is the controlling shareholder of BGI Genomics, and MGI Tech is under the control of the same ultimate controlling shareholder, according to the notice. BGI Group built and manages the China National GeneBank, a national biological data and sample repository. DHS described the three companies together as "one of the largest advanced gene-sequencing and genetic-material collection enterprises in the world." The notice also said BGI Group conducts genetic testing including on genetic material of human beings sourced from the XUAR, and that BGI Genomics tests genetic material of plants, animals and bacterial diseases sourced from the region. The United States government also believes BGI Group tests genetic material of people from the region as well as that of plants and animals, Reuters reported.
Who Are BGI Genomics, MGI Tech and BGI Group?
BGI Group, formerly the Beijing Genomics Institute, traces its origins to 1999, when it was formed as a genetics research centre to take part in the Human Genome Project. It is headquartered in Yantian, Shenzhen, and has grown from a research institute known for decoding the DNA of pandas and rice plants into a diversified genomics company active in health testing and contract research. BGI Genomics, listed on the Shenzhen Stock Exchange under the code 300676, describes itself as a leading integrated provider of scientific technology services and precision medicine, using sequencing and bioinformatics technology for research institutions, medical facilities and public health organisations, including work on birth defects, tumours and serious illnesses.
MGI Tech, listed on the Shanghai Stock Exchange under the code 688114, makes and sells DNA sequencing instruments, reagents and related products for life-science research. Its work includes high-throughput gene sequencers and multi-omics platforms covering genetic sequencing, medical imaging and laboratory automation. In practical terms, BGI Genomics provides testing and analysis services, while MGI Tech provides the machines and consumables that laboratories use to do sequencing themselves. That distinction matters for the import ban, because the listing can affect both finished testing services and the instruments and reagents that move across borders, depending on how a shipment is classified and what evidence an importer can provide.
How the UFLPA Presumption Works for Importers
The UFLPA, a United States law passed in 2021, creates a rebuttable presumption that goods mined, produced or manufactured wholly or in part in the XUAR, or by a listed entity, are prohibited from entering the United States. An importer can overcome the presumption only by showing, under the law's evidentiary requirements, that the goods were not made with forced labour. Until that showing is made, CBP is instructed to stop the goods. The burden therefore sits with the importer, not with CBP to prove forced labour in each shipment. That burden is the practical core of the US BGI import ban for any buyer whose supply chain touches the three listed companies. For laboratories, hospitals and research buyers, the immediate practical questions are which suppliers and products fall within the listing, what documentation a shipment will need, and whether an alternative supplier can be used while a rebuttal is prepared. This article does not give legal advice; importers facing a detained shipment need advice on the specific facts of that shipment.
The listing also raises a question that the wire reports did not fully answer: how much of the three companies' business actually reaches the United States. MGI Tech said its business activities in the United States represent a limited part of its overall business. BGI Genomics said its business in the United States is limited and that it does not expect the designation to have a significant impact on its overall operations, according to reporting on the companies' responses. Those statements, if correct, would limit the direct commercial shock in the United States, even as the political and reputational effects remain large. No share-price or revenue conclusion should be drawn from the listing alone without the companies' own filings.
What BGI and MGI Said in Response
MGI Tech rejected the allegations, saying they were inconsistent with the facts. In a statement reported by Reuters, the company said: "We have zero tolerance for forced labor in any form." BGI Genomics and BGI Group have also said they are not engaged in any form of forced labour, Reuters reported on 29 October. In the past, BGI Group has denied assertions that it participated in the collection, storage or analysis of personal genetic information to infringe on human rights, and it has denied supporting the surveillance of minorities. Those denials are central to the dispute: the United States case rests on DHS's stated belief about testing in Xinjiang, while the companies say the allegations do not match the facts of their work.
How China Responded on 29 October 2026
China's commerce ministry condemned the United States move on Thursday 29 October, saying the listing was contrary to the consensus reached by the two heads of state. The ministry said the United States should immediately cease "political manipulation, smear campaigns, and unreasonable suppression of Chinese enterprises," and said Beijing would take steps to safeguard its interests. Beijing said the ban had no factual basis and accused Washington of using human rights as a pretext for unilateral protectionism. The ministry also said workers of all ethnic groups in Xinjiang enjoy freedom and equal employment opportunities and that their labour rights are effectively protected by law, according to reporting on its statement.
Beijing has regularly dismissed accusations of forced labour and other abuses against Uyghurs and other Muslim minorities in Xinjiang. A group of United Nations experts said in January that there was a "persistent pattern" of alleged forced labour affecting Uyghur, Kazakh and Kyrgyz minority groups as well as Tibetans in Xinjiang and across multiple provinces of China, Reuters reported. Beijing rejected those allegations as groundless. The United Nations warned in 2022 of possible crimes against humanity in the region, including the detention of more than a million Uyghurs and other Muslim minorities in camps, according to reporting on that warning. Readers should treat the United States allegation, the companies' denial and China's denial as competing claims in an unresolved dispute, not as a settled court finding.
Why the US BGI Import Ban Matters Beyond Genomics
The ban arrived during a fragile trade truce between China and the United States, and it follows a pattern of tit-for-tat measures in technology. China banned imports of sequencing equipment from San Diego-based Illumina in March 2025, minutes after an additional 10 percent United States tariff on Chinese goods took effect, Reuters reported. Illumina said in November 2025 that China's Ministry of Commerce said it would lift the ban, but that the company would remain on China's Unreliable Entities List, meaning purchases of its instruments would still require government approval. The US-China trade framework agreed in Kuala Lumpur took 100 percent tariffs off the table, but the BGI listing shows that targeted restrictions can continue even while headline tariffs are paused. China's export controls on next-generation solar technology are another example of controls being used as leverage in the same contest.
Genomics has also become a national-security issue in Washington, not only a trade issue. The House Select Committee on the CCP welcomed the DHS move, with Chairman John Moolenaar describing BGI as China's state-controlled DNA collection company and a national security threat, and thanking the administration for stopping the company's products from being imported. The committee also pointed to BGI having been added to the Pentagon's 1260H list in June, alongside dozens of other Chinese companies, and to the BIOSECURE Act, which it said was signed into law in December to protect Americans' medical data from BGI and Wuxi Apptec. Separately, the administration stepped up pressure on China in the same week on three fronts, including the genomics listing, the suspension of a visa-free travel programme for Chinese visitors to the Northern Mariana Islands, and the designation of Chinese-funded university centres as national security threats, according to reporting on those measures. US pressure on allies over secondary tariffs shows the same administration pressing partners as well as Beijing.
What Happens Next
Three questions will decide what the US BGI import ban means in practice. First, will any importer try to rebut the presumption for a specific shipment, and what evidence will CBP accept? Second, will Beijing announce concrete countermeasures beyond its statement that it will safeguard its interests, and will those measures touch Illumina, other United States genomics suppliers, or wider trade? Third, will the dispute be raised in United States-China talks, or will it sit alongside the trade truce as a separate security action? The answers will matter most to laboratories and hospitals that rely on sequencing instruments and reagents, to researchers who use BGI testing services, and to investors trying to judge how far Washington and Beijing will take technology restrictions. For now, the verified facts are the listing itself, the 29 October start of the border presumption, the companies' denials, and China's condemnation. Everything beyond that is still to be decided.
Sources: Reuters reporting on the United States ban on imports from three Chinese genomics companies on 28 October 2026 and on China's condemnation on 29 October 2026; United States Department of Homeland Security announcement and Federal Register notice on the UFLPA Entity List additions, as reported by Reuters and the Digital Free Press; House Select Committee on the CCP statement on the DHS ban; company statements from MGI Tech, BGI Genomics and BGI Group as reported by Reuters; BGI Group and MGI Tech company descriptions; reporting on the Illumina restrictions and on the wider United States measures in the same week.